File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The effect of 3 years of recombinant growth hormone therapy on glucose metabolism in short Chinese children with β-thalassemia major

TitleThe effect of 3 years of recombinant growth hormone therapy on glucose metabolism in short Chinese children with β-thalassemia major
Authors
Issue Date2000
PublisherFreund Publishing House, Ltd. The Journal's web site is located at http://www.freundpublishing.com/Journal_Pediatric_Endocrinology_Metabolism/JPEMprev.htm
Citation
Journal Of Pediatric Endocrinology And Metabolism, 2000, v. 13 n. 5, p. 545-552 How to Cite?
AbstractGrowth retardation and diabetes mellitus are common in children and adolescents with β-thalassemia major despite hypertransfusion regimen and iron chelation therapy. The purpose of this study was to investigate the effects of growth hormone (GH) treatment on glucose metabolism in children with β-thalassemia major. GH therapy for 3 years improved the height SD scores of eight short prepubertal Chinese children with β-thalassemia major from -2.15 ± 0.90 to -1.14 ± 0.78 (paired t-test, p = 0.01) without excessive advancement in bone age (ΔBA/CA = 0.95 ± 0.27). There was no deleterious effect on glucose metabolism with no change in fasting blood sugar, serum fructosamine, fasting and stimulated insulin to intravenous glucose infusion (sum of 1+3 min insulin, In 1+3'; incremental insulin 0-10 min area above fasting concentrations, ΔIn(Auc)0-10'; ratio of incremental 0-10 min insulin area above fasting concentrations over glucose area above fasting concentrations, Δ0-10'(auc)In/G; ratio of incremental 0-10 min insulin over peak glucose above basal 0-10 min, Δ0-10'In(AUC)/ΔG(Peak)), and glucose disappearance coefficient (K(g)). Short term GH therapy improves the height of children with β-thalassemia major but the effect of treatment on final height still needs to be determined.
Persistent Identifierhttp://hdl.handle.net/10722/170302
ISSN
2015 Impact Factor: 0.912
2015 SCImago Journal Rankings: 0.493
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorKwan, EYWen_HK
dc.contributor.authorTam, SCFen_HK
dc.contributor.authorCheung, PTen_HK
dc.contributor.authorLow, LCKen_HK
dc.date.accessioned2012-10-30T06:07:21Z-
dc.date.available2012-10-30T06:07:21Z-
dc.date.issued2000en_HK
dc.identifier.citationJournal Of Pediatric Endocrinology And Metabolism, 2000, v. 13 n. 5, p. 545-552en_HK
dc.identifier.issn0334-018Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/170302-
dc.description.abstractGrowth retardation and diabetes mellitus are common in children and adolescents with β-thalassemia major despite hypertransfusion regimen and iron chelation therapy. The purpose of this study was to investigate the effects of growth hormone (GH) treatment on glucose metabolism in children with β-thalassemia major. GH therapy for 3 years improved the height SD scores of eight short prepubertal Chinese children with β-thalassemia major from -2.15 ± 0.90 to -1.14 ± 0.78 (paired t-test, p = 0.01) without excessive advancement in bone age (ΔBA/CA = 0.95 ± 0.27). There was no deleterious effect on glucose metabolism with no change in fasting blood sugar, serum fructosamine, fasting and stimulated insulin to intravenous glucose infusion (sum of 1+3 min insulin, In 1+3'; incremental insulin 0-10 min area above fasting concentrations, ΔIn(Auc)0-10'; ratio of incremental 0-10 min insulin area above fasting concentrations over glucose area above fasting concentrations, Δ0-10'(auc)In/G; ratio of incremental 0-10 min insulin over peak glucose above basal 0-10 min, Δ0-10'In(AUC)/ΔG(Peak)), and glucose disappearance coefficient (K(g)). Short term GH therapy improves the height of children with β-thalassemia major but the effect of treatment on final height still needs to be determined.en_HK
dc.languageengen_US
dc.publisherFreund Publishing House, Ltd. The Journal's web site is located at http://www.freundpublishing.com/Journal_Pediatric_Endocrinology_Metabolism/JPEMprev.htmen_HK
dc.relation.ispartofJournal of Pediatric Endocrinology and Metabolismen_HK
dc.subject.meshBlood Glucose - Metabolismen_US
dc.subject.meshBody Heighten_US
dc.subject.meshChilden_US
dc.subject.meshFemaleen_US
dc.subject.meshFructosamine - Blooden_US
dc.subject.meshGlucose Tolerance Testen_US
dc.subject.meshGrowth Disorders - Drug Therapy - Etiology - Physiopathologyen_US
dc.subject.meshGrowth Hormone - Therapeutic Useen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshOsteogenesisen_US
dc.subject.meshBeta-Thalassemia - Complications - Physiopathologyen_US
dc.titleThe effect of 3 years of recombinant growth hormone therapy on glucose metabolism in short Chinese children with β-thalassemia majoren_HK
dc.typeArticleen_HK
dc.identifier.emailCheung, PT: ptcheung@hku.hken_HK
dc.identifier.emailLow, LCK: lcklow@hkucc.hku.hken_HK
dc.identifier.authorityCheung, PT=rp00351en_HK
dc.identifier.authorityLow, LCK=rp00337en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid10803873-
dc.identifier.scopuseid_2-s2.0-0034060104en_HK
dc.identifier.hkuros48469-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0034060104&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume13en_HK
dc.identifier.issue5en_HK
dc.identifier.spage545en_HK
dc.identifier.epage552en_HK
dc.identifier.isiWOS:000086787400012-
dc.publisher.placeIsraelen_HK
dc.identifier.scopusauthoridKwan, EYW=7006484387en_HK
dc.identifier.scopusauthoridTam, SCF=7202037323en_HK
dc.identifier.scopusauthoridCheung, PT=7202595465en_HK
dc.identifier.scopusauthoridLow, LCK=7007049461en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats